The Introduction of Impella 5.5 in Cardiogenic Shock: A Single-Center, Retrospective Propensity Score-Matched Analysis.

ABSTRACT: Background/Objectives: Impella 5.5 provides a higher flow rate than smaller microaxial pumps and has been increasingly adopted for cardiogenic shock (CS). This study aimed to evaluate whether its introduction into our Shock Team program in 2023 improved outcomes compared with a historical cohort supported with other mechanical circulatory support (MCS) devices. Methods: We retrospectively analyzed patients with CS treated with MCS between 2020 and 2024 at a tertiary center. The Impella 5.5 group (n = 17) included patients managed after device implementation, either as stand-alone or sequential therapy. The historical cohort comprised 40 patients treated with ECMO, Impella CP, CentriMag, or IABP prior to 2023. Propensity score matching (age, sex, etiology, lactate, SCAI stage)

SUBMITTER: Bochenek M 

PROVIDER: S-EPMC12610547 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature